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Research continues to identify adverse effects
of lead at progressively lower levels of expo-
sure, thereby increasing the number of chil-
dren estimated to be at risk for cognitive
impairment (1–4). Further, public health pro-
grams have achieved limited success in reduc-
ing Pb exposures through primary prevention,
despite the recognized importance of this goal
(5). This underscores the need to develop
improved intervention strategies, particularly
for moderately Pb-poisoned children who
have blood Pb (BPb) levels between 20 and
45 µg/dL.
Succimer [Chemet, meso-2,3-dimercapto-
succinic acid, DMSA] is considered to be a
safe and effective chelating agent for the
treatment of Pb poisoning in humans (6–9).
However, there remain a number of out-
standing questions that should be addressed
to better evaluate the overall utility of suc-
cimer treatment for moderately Pb-poisoned
children. For example, the effects of succimer
on the gastrointestinal (GI) absorption and
retention of Pb from exposures suffered con-
currently with treatment are not well known.
Effects of oral succimer on GI Pb absorption
have ranged from no detectable effect in
humans (8) to a decrease in rats (10). Other
Pb-chelating agents [CaNa2EDTA, citrate,
penicillamine, and 2,3-dimercapto-1-
propanol, also known as British Anti-
Lewisite (BAL)] have been shown to increase
GI Pb absorption, and in some cases (citrate,
penicillamine, and BAL) this has resulted in
an increase in body Pb burden (11). 
Concern over the effects of oral succimer
on GI lead absorption is justified because
succimer exhibits high Pb-binding affinity
[Pb-DMSA chelate formation constant = 2.9
× 1017 (12)]. Also, the potential exists for
continued elevated, albeit lower, Pb expo-
sures during outpatient treatment with oral
succimer. This is because environmental Pb
exposures are often difﬁcult to identify and
effectively eliminate (13,14) and because the
availability of Pb-safe housing during outpa-
tient chelation treatment is often limited. 
Here we used a juvenile nonhuman pri-
mate model of moderate childhood Pb
intoxication and a sensitive double stable Pb
isotope tracer methodology to determine
whether oral succimer chelation affects the
GI absorption and whole-body retention of
Pb. This investigation was a substudy of a
larger study that investigated the efﬁcacy of
succimer chelation therapy for reducing tis-
sue Pb concentrations and alleviating cogni-
tive impairment. Results from that larger
study have been reported elsewhere (15–17)
or are forthcoming.
Materials and Methods
Study design/treatments. The present study
was composed of a 1 × 2 factorial design (Pb
exposed  × vehicle or succimer; n =
8–9/group). Animals were exposed to Pb
daily for 1 year to achieve and maintain tar-
get BPb levels of 35–40 µg/dL; animals were
then treated with two successive 19 day regi-
mens of succimer or vehicle starting at 53
and 65 weeks of age. The present study was
conducted during the second chelation at 65
weeks of age. Thus, daily Pb exposure in
these animals ceased 12 weeks before this
study was conducted. 
Animals. Seventeen female infant rhesus
monkeys (Macaca mulatta) born at the
Harlow Center for Biological Psychology
breeding colony were used in this study. We
assigned animals to vehicle (n = 8) and suc-
cimer (n = 9) treatment groups at birth.
Complete details of the animal recruitment
and care procedures are reported elsewhere
(15,17). Brieﬂy, the infants were housed in a
single cage with their mothers until weaning
at age 26 weeks; they were subsequently
housed in groups of five females and one
nonstudy male in group cages. After wean-
ing, the monkeys were maintained on Purina
Monkey Chow (#5037; PMI Feeds, Inc., St.
Louis, MO) ad libitum. All procedures
related to animal care conformed to the
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Although succimer (Chemet, meso-2,3-dimercaptosuccinic acid, DMSA) is considered to be a safe
and effective chelating agent for the treatment of lead poisoning in humans, there is concern that
it may increase the gastrointestinal (GI) absorption and retention of Pb from exposures suffered
concurrent with treatment. This concern is justified because the availability of Pb-safe housing
during outpatient treatment with oral succimer is limited. We used a juvenile nonhuman primate
model of moderate childhood Pb intoxication and a sensitive double stable Pb isotope tracer
methodology to determine whether oral succimer chelation affects the GI absorption and whole-
body retention of Pb. Infant rhesus monkeys (n = 17) were exposed to Pb daily for 1 year post-
partum to reach and maintain a target blood lead (BPb) level of 35–40 µg/dL. Animals were
administered succimer (n = 9) or vehicle (n = 8) over two successive 19 day succimer treatment
regimens beginning at 53 and 65 weeks of age. The present study was conducted over the second
chelation regimen only. Animals received a single intravenous (iv) dose of stable 204Pb tracer (5
µg, 24.5 nmol) followed by a single oral dose of stable 206Pb tracer (72.6 µg, 352 nmol) immedi-
ately before chelation, in order to specifically evaluate GI Pb absorption and whole-body Pb
retention with treatment. We collected complete urine and fecal samples over the ﬁrst 5 days and
whole blood over the ﬁrst 8 days of treatment for analyses of stable Pb isotopes using magnetic
sector inductively-coupled plasma mass spectrometry. Results indicate that succimer signiﬁcantly
reduced the GI absorption of Pb (vehicle, 64.9% ± 5.5; succimer, 37.0% ± 5.8; mean ± SEM).
Succimer also signiﬁcantly increased the urinary excretion of endogenous Pb by approximately 4-
fold over the vehicle treatment, while endogenous fecal Pb excretion was decreased by approxi-
mately 33%. Finally, although succimer reduced the whole-body retention of endogenous Pb by
approximately 10% compared to vehicle, the majority (77%) of the administered internal dose of
Pb tracer was retained in the body when assessed after 5 days of treatment. These data do not
support the concern that succimer treatment increases GI Pb absorption. Key words: 2,3-dimer-
captosuccinic acid, absorption, chelation, Chemet‚ lead, lead exposure, nonhuman primate, suc-
cimer. Environ Health Perspect 109:613–619 (2001). [Online ________]
http://ehpnet1.niehs.nih.gov/docs/2001/109p613-619cremin/abstract.htmlguidelines set forth in the Guide for the Care
and Use of Laboratory Animals (18).
Lead exposure. We orally administered
lead acetate (Fisher Chemical, Fairlawn, NJ)
to the infant monkeys in a solution of Similac
with iron formula (Abbott Laboratories,
Columbus, OH) daily between 1430 and
1630 hr beginning on day 8 postpartum
through age 26 weeks. After weaning the
monkeys received their oral Pb dose dissolved
in apple juice. The required dose of Pb acetate
was dissolved in 50% glucose before being
added to the Similac or apple juice. Lead was
administered daily in amounts targeted to
produce BPb levels of approximately 35–40
µg/dL. The Pb dose was adjusted biweekly as
needed to maintain the target BPb level. Oral
Pb exposure was discontinued immediately
before the ﬁrst succimer chelation period (i.e.,
at the end of 52 weeks of age). Thus, daily Pb
exposure to the animals ceased 12 weeks
before this study was conducted. The target
BPb level of 35–40 µg/dL was chosen because
it is within the range of BPb levels at which
succimer is being used in children, and it is
also within the range of the BPb levels in chil-
dren (20–45 µg/dL) participating in the suc-
cimer clinical trials (19). In previous studies,
we observed no overt signs of Pb toxicity (e.g.,
decreased weight gain, reduced appetite,
lethargy) in infant rhesus monkeys at chronic
BPb levels of 30–80 µg/dL (20,21).
Administration of intravenous 204Pb and
oral 206Pb stable isotope tracers. All animals
received 5 µg (24.5 nmol) of 204Pb stable iso-
tope tracer via a single intravenous (iv) injec-
tion within approximately 30 min before
beginning chelation treatment. The stable
204Pb tracer (204PbCO3, 99.71% 204Pb
enriched; National Institute of Standards and
Technology, Gaithersburg, MD) was pre-
pared by dissolving 204PbCO3 to a concen-
tration of 1,000 µg 204Pb/mL in ultrapure
1N HNO3. An aliquot of this solution was
evaporated to dryness and redissolved in acid-
ified (pH 2) sterile ultra-pure water (> 18
Mohm-cm2) to a concentration of 100 µg
204Pb/mL. For administration to the animals,
we diluted this solution into 1 mL sterile
saline (ﬁnal pH 7.0) immediately before dos-
ing. The Pb tracer vial was rinsed twice with
1 mL aliquots of sterile saline and the entire
contents (3 mL) administered to the animal. 
A single oral dose of 72.6 µg (352 nmol)
206Pb tracer was administered orally by
syringe within approximately 15 min after the
iv 204tracer dose. The stable 206Pb tracer
(206PbCO3, 99.66% 206Pb enriched, National
Institute of Standards and Technology,
Gaithersburg, MD) was prepared as described
above, except that apple juice was used in
place of sterile saline as the carrier/diluent.
Following delivery of the 3 mL dose of tracer,
the syringe was washed three times with apple
juice and the rinses given orally to ensure that
all the tracer was administered, resulting in a
total delivery of 12 mL apple juice. Food was
withheld for 20 hr before and 1.5 hr after
administration of the oral 206Pb dose to mini-
mize any confounding effects of the fed state
on GI Pb absorption.
This double stable Pb isotope tracer
method provided a means to accurately deter-
mine both the GI absorption and the whole-
body retention of Pb. The administered 206Pb
tracer was used to determine the GI absorp-
tion of Pb. We used the 204Pb tracer to cor-
rect for the excretion of endogenous Pb into
the feces (e.g., biliary) that would otherwise
confound the measurement of GI Pb absorp-
tion based on the collection of oral 206Pb
tracer eliminated in the feces. We also used
the administered 204Pb tracer and the
absorbed oral 206Pb tracer to evaluate the
whole-body retention of Pb. Notably, data on
the use of this tracer method in these animals
has demonstrated no measurable difference in
the chelation of the 204Pb tracer versus Pb
absorbed from chronic oral exposures (17).
This suggests that iv-administered stable Pb
isotope accurately reﬂects the fate of chelat-
able “total” Pb in the body. For clarity in this
paper, we refer to body Pb accumulated from
the chronic oral exposures administered over
the ﬁrst year of life as “inherent” body Pb.
Succimer treatment. Succimer (as
Chemet) was administered following manu-
facturers instructions and standard clinical
procedures (7). Treatment with oral succimer
or vehicle began at a mean age of 53 weeks
(ﬁrst chelation) and again at 65 weeks (second
chelation). The present study was conducted
over the second chelation regimen. Succimer
was administered at a dose of 30 mg/kg/day
divided into three doses per day for 5 days
(administered at 0900, 1600, and 2300 hr);
treatment continued for an additional 14 days
at 20 mg/kg/day divided into two doses per
day (administered at 0900 and 2300 hr), for a
total 19 day treatment regimen. Succimer
dosing commenced within approximately 15
min after administration of the oral 206Pb
tracer dose. Succimer was orally administered
in apple juice vehicle via syringe within 15
min of dissolving the succimer to ensure max-
imum activity. The vehicle group received
succimer placebo that was obtained from the
pediatric clinical trials (19) and administered
as described above for succimer. 
Sample collection. All sample collection,
storage, and laboratory ware (i.e., Teflon,
polyethylene, polypropylene, and stainless
steel) were acid-cleaned using established
procedures (22). Sample processing and
analyses were performed using reagents that
were double sub-boiling quartz-distilled,
high-purity grade, and ultrapure water (> 18
Mohm-cm2).
Blood. Whole blood samples (0.5–1 mL)
were collected between 0900 and 1100 hr by
femoral venipuncture into heparinized
Vacutainer tubes (#367734; Becton-
Dickinson, Franklin Lakes, NJ) and stored
frozen until analyzed. Samples were collected
from all animals on days 0, 1, 3, 5, and 8 rel-
ative to the start of chelation on day 0. 
Urine and feces. One day before the
start of chelation, individual animals were
placed in stainless steel metabolic cages,
where they remained throughout the ﬁrst 5
days of treatment (for a total of 6 consecu-
tive days) in order to facilitate complete
urine and fecal collections. Except for the
overnight food fast before receiving tracer,
animals were given free access to food and
water while in the metabolic cages. Urine
collection bottles were changed and feces
collected at 24-hr intervals. 
The metabolic cages were modified for
this study to minimize the transfer of food
and fecal material into the collected urine
sample (16). To minimize sample contami-
nation with Pb, cages were cleaned daily by
rinsing with ultrapure water and weekly (i.e.,
between placing new animals in the cage)
using soap and water, acid-washing with
dilute HNO3, and rinsing with ultrapure
water. Immediately following collection of a
24-hr urine sample, the total volume was
recorded and an 8-mL subsample of urine
was removed and filtered through an acid-
cleaned 0.5-µm Teflon syringe filter to
remove any suspended particles. Samples
were filtered into a polyethylene bottle and
stored frozen until analyzed. Urine sample
collection blanks were collected to evaluate
the possibility of sample contamination with
Pb from food, feces, and the metabolic
cages, as described elsewhere (16). Fecal
samples were stored frozen in acid-cleaned
polypropylene jars.
Sample processing and analyses. All sam-
ple processing and analyses were conducted
at the University of California, Santa Cruz,
using trace metal clean techniques under
HEPA filtered-air conditions to minimize
contamination of the samples (22). We
thawed and acidified (pH < 2) daily urine
samples with 16N Q-HNO3 (Fisher
Scientiﬁc, Pittsburgh, PA) to prevent loss of
trace elements to the walls of the polyethyl-
ene storage bottles; we analyzed samples
directly by inductively coupled plasma mass
spectrometry (ICP-MS) (17). For fecal sam-
ples, we added ultrapure water to the daily
sample (4 parts water:1 part feces, v/w), and
subsequently homogenized the sample using
a stainless steel blender. To obtain a represen-
tative sub-sample, we used a Teﬂon stir bar
to stir the homogenate; we then transferred a
subsample (> 1 g) to a Teflon vial using a
large bore pipette tip. The fecal subsample
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weight, digested for 8 hr in 2 mL hot 16N
Q-HNO3, evaporated to dryness, and redis-
solved in 1N Q-HNO3 for ICP-MS analysis
(22,23). Blood samples were thawed and an
aliquot was mixed with 1N Q-HNO3; the
sample was vortexed vigorously, the formed
precipitate was allowed to settle, and the
supernatant was transferred and analyzed by
ICP-MS. National Institute of Standards and
Technology (NIST) standard reference mate-
rial (SRM) 955A (Pb in blood), SRM 2670
(urine), and SRM 1577b (bovine liver) were
used to evaluate procedural accuracy of the
sample preparation and Pb analyses. 
We measured sample Pb levels using a
Finnigan MAT element magnetic sector-ICP
mass spectrometer (Finnigan MAT, San Jose,
CA) in multi-isotope counting mode, mea-
suring masses of 201Hg (used to correct for
204Hg interference of 204Pb), 204Pb, 206Pb,
207Pb, 208Pb, and 209Bi, with 209Bi used as an
internal standard (23). External standardiza-
tion for Pb was via the NIST SRM 981 iso-
topic standard and a certified Spex Pb
standard (Spex Industries Incorporated,
Edison, NJ) that had been independently iso-
topically characterized via thermal ionization
mass spectrometry. Based on the SRMs, the
measurement accuracy for Pb was 101% ±
5% relative SD for analyzed Pb concentra-
tions > 0.05 ppb, with an analytical detection
limit of 0.01 ppb (23).
Calculations and deﬁnitions. Sample Pb
isotope concentrations are expressed as
nanomoles Pb isotope per gram of dry
weight for feces or nanomoles per milliliter
for blood and urine. We calculated values for
endogenous Pb accumulated from the 1-year
oral Pb dosing period (i.e., inherent Pb) and
for the contribution from the oral and intra-
venous stable Pb isotope tracers. The levels
of sample total Pb reflect the sum of the
inherent Pb and the administered stable Pb
isotope tracers, as expressed below: 
Total Pb= Total 204Pb + Total 206Pb 
+ Total 207Pb + Total 208Pb, (1) 
where Total 204Pb includes the contributions
from inherent 204Pb + iv 204Pb tracer. Total
206Pb includes the contributions from inher-
ent 206Pb + oral 206Pb tracer.
The concentrations of stable Pb isotope
tracers for each collection day were unmixed
from these total values using the isotopic
ratio of the inherent Pb (determined in pre-
tracer day 0 samples):
204Pb Tracer = {[(208PbInherent/204PbInherent) 
– (208Pbday x/204Pbday x)] 
÷ (208PbInherent /204PbInherent)}
× 204Pbday x (2)
206Pb Tracer = {[(208PbInherent/206PbInherent )
– (208Pbday x/206Pbday x)] 
÷ (208PbInherent/206PbInherent )} 
× 206Pbday x (3) 
where Inherent equals nanomoles per milli-
liter of Pb isotope before administration of
either 204Pb tracer or 206Pb tracer (i.e., day
0). Day x equals nanomoles per milliliter of
Pb isotope in the sample collected on day x
of the succimer chelation period.
We calculated the daily total excretion of
each stable Pb isotope tracer by multiplying
the concentration of each Pb tracer in urine
and fecal samples by the amount of urine
and feces excreted on that day. The total
excretion of the Pb tracers for the 5 days of
the chelation period (days 1–5) were deter-
mined by summing the amounts calculated
for the individual days.
The following specific outcomes were
calculated to achieve the study objectives: 
Endogenous fecal excretion of absorbed oral
206Pb tracer = (206Pb tracer in blood 
÷ 204Pb tracer in blood) 
× 204Pb tracer in feces. (4)
(This calculation assumes that the ratio of
206Pb tracer:204Pb tracer excreted in the feces
is identical to that in the whole blood for
that collection day.) 
Fecal elimination of unabsorbed oral 
206Pb tracer = 206Pb tracer in feces 
– Endogenous fecal excretion of 
absorbed oral 206Pb tracer.  (5)
GI Absorption of oral 206Pb tracer (relative 
percent) = [(Oral dose 206Pb tracer 
– Fecal elimination of unabsorbed 
oral 206Pb tracer)
÷ Oral dose 206Pb tracer] × 100. (6)
Body retention of oral 206Pb 
tracer= Oral dose 206Pb tracer 
– (Fecal elimination of unabsorbed 
oral 206Pb tracer 
+ Totalurine + feces excretion of absorbed 
oral 206Pb tracer).  (7) 
Body retention of endogenous (iv) 204Pb 
tracer = Intravenous dose 204Pb tracer 
– (204Pb tracer in feces + 204Pb tracer 
in urine). (8) 
Because blood samples were collected
only on days 0, 1, 3, 5, and 8 of treatment,
it was necessary to interpolate blood tracer
values for treatment days 2 and 4 in order to
estimate the 206Pb tracer:204Pb tracer ratio of
blood on those treatment days. This was
done by fitting a first-order disappearance
equation to the measured blood tracer Pb
concentrations on days 0, 1, 3, and 5 for
each animal and then interpolating the daily
values for treatment days 2 and 4. The corre-
lation coefficients (r) for the best-fit lines
ranged from 0.939 to 0.994, thereby validat-
ing this approach. These interpolated values
were then used in calculating the daily
endogenous fecal excretion of absorbed oral
206Pb tracer (Equation 4).
Statistical analyses. The daily fecal elimi-
nation of unabsorbed 206Pb tracer, concen-
trations of blood total Pb, and BPb
tracer:inherent Pb ratio data were analyzed
using repeated measures analysis of variance
(RM-ANOVA), where the effect of treat-
ment (succimer or vehicle) was the between
subjects factor and the effect of collection
day was the within-subjects factor. All
remaining data were analyzed using analysis
of variance (ANOVA). We used the breed-
ing cohort as a blocking factor in all
ANOVA analyses. For RM-ANOVA, we
used the Greenhouse-Geisser adjusted F sta-
tistic if the test of sphericity was signiﬁcant.
For significant ANOVA effects, differences
among means were determined using the
Tukey pairwise-comparison test. We consid-
ered p-values < 0.05 statistically significant
for all tests. All analyses were conducted
using SAS Version 6.12 (24).
Results
Gastrointestinal absorption of oral Pb. The
daily fecal elimination of unabsorbed oral
206Pb tracer was significantly increased by
succimer (Figure 1A). There was no succimer
× collection day interaction, implying that
the effect of succimer on fecal elimination of
unabsorbed Pb was consistent across treat-
ment days 1–5. When the daily fecal Pb
excretion was averaged across treatment
groups, it was apparent that the majority
(> 96%) of unabsorbed fecal 206Pb tracer was
eliminated over treatment days 1 and 2 and
declined substantially to near 0 by day 5 in
these juvenile monkeys (Figure 1A). These
results indicate that the 5-day fecal collection
period was adequate to recover essentially all
of the unabsorbed oral 206Pb tracer that was
eliminated in the feces.
Consistent with the above results, suc-
cimer signiﬁcantly decreased the GI absorp-
tion of oral 206Pb tracer by approximately
43% relative to the vehicle group (Pb absorp-
tion was 64.9% ± 5.5 SEM for vehicle and
37.0% ± 5.8 SEM for succimer; Figure 1B).
Data from one vehicle-group monkey was
excluded from the statistical analysis as an
outlier because its absorption and body reten-
tion of oral 206Pb tracer and its fecal elimina-
tion of unabsorbed oral 206Pb tracer were
> 1.5 interquartile ranges from the 75th per-
centile. When the observations from this ani-
mal were included in the statistical analysis,
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GI Pb absorption was 56% + 10 SEM for
vehicle and 37% + 6 SEM for succimer), but
differences between treatments were no
longer statistically significant. A possible
explanation for this outlying value is that this
subject inadvertently received a larger dose of
oral 206Pb tracer than was intended. This ani-
mal was not an outlier for the other out-
comes measured (e.g., 204Pb tracer measures),
and its inclusion in the statistical analysis of
those other measures did not affect the out-
come of those analyses. Nonetheless, for con-
sistency, we excluded all measurements from
this monkey from the ﬁnal statistical analysis
and presentation of all data. 
Urinary and endogenous fecal excretion
of body Pb. Succimer signiﬁcantly increased
the urinary excretion of total Pb (i.e., Pb
tracers + inherent non-tracer Pb), but had no
measurable effect on the fecal excretion of
endogenous total Pb (Figure 2A). The net
result was a signiﬁcant overall 189% increase
in the combined (urine + feces) excretion of
total Pb with succimer treatment over the
vehicle group. Excretion of the 204Pb and
206Pb tracers (Figure 2B,C) did not have a
substantial influence on the excretion of
total Pb, as evidenced by the fact that the
combined excretion of both tracers com-
posed < 6% of the urinary excretion and
< 4% of the fecal excretion of total Pb. This
point is further substantiated by the fact that
statistical analysis of inherent (i.e., non-
tracer) Pb values produced the same out-
come as the analyses of the total Pb values
(data not shown). As stated above, inherent
Pb is composed predominantly of non-tracer
Pb accumulated from the chronic oral Pb
exposures received until 52 weeks of age. 
Notably, the urinary and fecal excretion
patterns of total Pb, and iv 204Pb and oral
206Pb tracers were similar within each treat-
ment group, when the excretion of each tracer
is expressed relative to its internal (204Pb) or
absorbed (206Pb) dose (Figure 2). For this, the
internal dose of 204Pb was equivalent to the
entire administered iv dose (24.5 nmol),
whereas the absorbed dose of the oral 206Pb
tracer was the calculated amount absorbed
across the GI tract for each animal. The lack
of a statistically signiﬁcant effect of succimer
on the excretion of total Pb and 206Pb tracer
(Figure 2A,B) compared to 204Pb tracer
(Figure 2C) is likely due to increased variabil-
ity in the former data, rather than in a speciﬁc
effect of succimer per se. Overall, the effects
of succimer on 204Pb tracer (Figure 2C) may
more accurately reﬂect the effects of succimer
on endogenous body Pb because all animals
received the same dose and the 204Pb tracer
was administered directly into the circulation.
The qualitative similarity in effects of suc-
cimer treatment on the excretion of the oral
206Pb and iv 204Pb tracers substantiates the
use of this stable isotope tracer method for the
assessment of the effects of succimer on GI Pb
absorption and body Pb retention. These data
also indicate that once in the body all sources
of excretable Pb behaved similarly, regardless
of whether the Pb originated from the oral
(206Pb tracer), iv (204Pb tracer), or inherent
(chronic through age 52 weeks) exposures.
Body retention of Pb. Succimer reduced
the body retention of endogenous Pb by
approximately 10% compared to the vehicle
group, based on assessment of both the orally
administered 206Pb and iv administered 204Pb
tracers, although only the effect on 204Pb
tracer was statistically signiﬁcant (Figure 3).
This is likely due to the confounding effects
of interanimal differences in the GI absorp-
tion of 206Pb tracer. It is noteworthy that the
apparent benefits of succimer treatment are
substantially greater when we consider its efﬁ-
cacy for both reducing GI Pb absorption and
increasing excretion of body Pb relative to the
vehicle treatment. This greater overall beneﬁt
of succimer treatment is substantiated by the
observation that the dose of oral 206Pb tracer
remaining in the body at the end of the col-
lection period was decreased signiﬁcantly by
44% versus the vehicle group, which consid-
ers losses from both fecal elimination of unab-
sorbed Pb and total excretion (urine +
endogenous fecal) of absorbed Pb.
BPb concentrations over treatment.
Succimer significantly reduced whole BPb
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Figure 1. Effect of oral succimer on (A) the daily fecal elimination of unabsorbed oral 206Pb tracer and (B)
the GI absorption of oral 206Pb tracer (see “Materials and Methods” for details). The bars represent mean ±
SEM for the vehicle (n = 7) and succimer (n = 9) groups. Succimer increased oral 206Pb tracer elimination in
the feces according to a RM-ANOVA (p < 0.05). Day of treatment means with different superscripts differ
according to Tukey’s test (p < 0.05). 
*Succimer group differs from the vehicle group according to ANOVA (p < 0.05).
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Figure 2. Effect of oral succimer on (A) urinary excretion and endogenous fecal excretion of total Pb
(inherent Pb + Pb isotope tracers); (B) urinary and fecal excretion of oral 206Pb tracer over the ﬁrst 5 days
of treatment; and (C) urinary and fecal excretion of endogenous 204Pb tracer over the ﬁrst 5 days of treat-
ment. The bars represent mean ± SEM for the vehicle (n = 7) and succimer (n = 8–9) groups. In (B), suc-
cimer did not measurably affect urinary or fecal excretion of the oral 206Pb tracer when the tracer is
expressed as a percentage of the amount absorbed from the GI tract. In (C), succimer increased urinary
excretion and decreased fecal excretion of endogenous 204Pb tracer (ANOVA, p < 0.05), when tracer is
expressed as a percentage of the amount injected iv. 
*Succimer increased urinary excretion of total Pb versus vehicle according to ANOVA (p < 0.05). concentrations measured on days 1, 3, 5, and
8 of the treatment period, when these values
were normalized to initial concentrations
(i.e., percentage of day 0 values for each ani-
mal) (Figure 4). When analyses were con-
ducted using the absolute (nonnormalized)
data, succimer treatment was found to signif-
icantly reduce BPb levels only on days 3 and
5 (Figure 4B). This latter outcome is attrib-
uted to interanimal variability in initial BPb
levels within each treatment group, which
was factored out when the data were normal-
ized to each animal’s day 0 BPb value.
Notably, BPb levels in the vehicle-treated
group did not measurably decline over the 8
days of treatment (Figure 4), which is attrib-
utable to the fact that Pb exposure ceased
immediately before the first chelation regi-
men 12 weeks earlier. It is also noteworthy
that the BPb levels in these animals were not
increased by the administered stable Pb iso-
tope tracers. For instance, the 204Pb tracer
was on average only 0.82% ± 0.18 SEM of
the total BPb for the vehicle group and only
1.0% ± 0.17 for the succimer group, whereas
the 206Pb tracer was 3.1% ± 0.92 and 1.3% ±
0.35 of total BPb for the vehicle and suc-
cimer groups, respectively. 
Succimer did not affect the ratio of 204Pb
tracer:inherent Pb in the blood because that
ratio was not measurably different between
the vehicle and succimer groups on any treat-
ment day (data not shown). This outcome
further substantiates that endogenous body
Pb responded similarly to succimer, regardless
of its source of exposure (i.e., inherent Pb, iv
administered 204Pb tracer). This was also
apparent from the results on the excretion of
endogenous Pb presented above (urinary and
endogenous fecal excretion of body Pb). In
contrast, succimer signiﬁcantly decreased the
ratio of oral 206Pb tracer:inherent Pb in the
blood by approximately 70%, and this
decrease persisted throughout treatment days
1–8 (data not shown). This outcome may be
simply attributed to the effect of succimer on
reducing the absorption of the oral 206Pb
tracer, which resulted in a reduced appearance
of 206Pb tracer in the blood and hence a lower
206Pb tracer:inherent Pb ratio in blood. 
Discussion
Succimer decreased gastrointestinal absorp-
tion of oral Pb. We observed that oral suc-
cimer treatment significantly decreased (by
43%) the GI absorption of Pb that was pre-
sent in the GI tract concurrent with begin-
ning treatment. This effect is demonstrated
not only by the increased fecal recovery of
unabsorbed 206Pb tracer in the succimer
group (Figure 1A) but also by the decreased
appearance of oral 206Pb tracer in the circula-
tion compared to the vehicle controls. The
latter is evidenced by the ratio of 206Pb
tracer:inherent Pb in blood, which was
reduced by approximately 70% with succimer
treatment (data not shown). Moreover, it is
clear that this latter result is not due to a dif-
ferent effect of succimer on inherent versus
tracer Pb within the body (e.g., Pb in the cir-
culation) per se because succimer treatment
had no measurable effect on the ratio of iv
204Pb tracer:inherent Pb. 
These results substantially extend previous
studies that have investigated the effects of
succimer on GI Pb absorption. In a study in
rodents, Kapoor et al. (10) administered a sin-
gle radioactive Pb tracer dose followed by a
single dose of DMSA (~ 20 mg/kg) and
found that oral succimer decreased GI Pb
absorption, although succimer administered
via intraperitoneal injection caused an oppo-
site increase in GI Pb absorption. A more
recent study in non-Pb exposed adult humans
used a stable Pb isotope tracer (200 µg 204Pb
administered orally) method and a single dose
of oral succimer (0, 10, or 30 mg/kg) and
found that succimer had no measurable effect
on GI Pb absorption (8). However, trends in
those data suggested that GI Pb absorption
was enhanced by succimer. There are several
reasons, including a possible age effect, that
may account for these study differences. The
adult human study used a lower oral Pb tracer
dose (~ 2.5 µg or 12 nmol 204Pb/kg body
weight), a single oral dose of succimer, and a
shorter study duration after succimer and Pb
dosing (~ 26 hr), the latter of which may not
have been sufﬁcient for complete fecal collec-
tion of unabsorbed Pb tracer. By comparison,
in the present study we used a higher oral Pb
tracer dose of approximately 25 µg or 121
nmol 206Pb/kg body weight, a succimer regi-
men of three divided doses per day for multi-
ple days, and complete urine and fecal
collections over the ﬁrst 5 days of treatment.
Succimer significantly increased the
excretion of Pb in urine. The effect of suc-
cimer treatment to signiﬁcantly increase the
excretion of Pb in the urine is consistent
with the action of this drug to form aqueous
soluble chelates with Pb (12), as well as with
a large body of clinical and laboratory evi-
dence showing increased urinary excretion of
Pb with treatment (1,17,25,26). This effect
was similar for both the iv-administered
204Pb tracer and the oral 206Pb tracer that
had been absorbed, and for the urinary
excretion of inherent body Pb originating
from the chronic oral Pb exposures (Figure
2). Although not apparent from these data,
other stable Pb isotope tracer data from the
larger cohort of monkeys (n = 48) of the par-
ent study indicate that succimer chelates and
removes Pb from labile soft tissue compart-
ments and not from the skeleton (17). 
Succimer tended to reduce the excre-
tion of endogenous Pb via the fecal route
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Figure 3. Effects of oral succimer on retention of
absorbed GI (oral 206Pb tracer) and endogenous (iv
204Pb tracer) Pb expressed as a percentage of the
internal dose. The internal dose is the amount of
the endogenous 204Pb tracer injected iv or the
amount of the oral 206Pb tracer absorbed from the
GI tract. The sum of the tracer Pb retained over
the ﬁrst 5 days of treatment is expressed as a per-
centage of the internal dose, which equals the
amount of oral 206Pb tracer absorbed or the
amount of 204Pb tracer that was injected. The bars
represent mean ± SEM for the vehicle (n = 7) and
succimer (n = 9) groups. 
*Succimer group differs from the vehicle group according
to an ANOVA (p < 0.05).
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Figure 4. Effects of oral succimer on total BPb (inherent Pb + Pb isotope tracers) concentrations (A)
expressed as a percentage of the initial day 0 value within each animal and (B) expressed as absolute
total BPb levels (µg/dL) for the vehicle (blue; n = 7) and succimer (red; n = 9) groups. The day 0 sample
was collected before the tracers and succimer were administered. Means with different superscripts dif-
fer according to Tukey’s test (p < 0.05). In (B), the succimer group differs from the vehicle group only on
treatment days 3 and 5 according to Tukey’s test (p < 0.05; superscripts were omitted for clarity).compared to the vehicle treatment (Figure 2).
Although this effect reached statistical signiﬁ-
cance only for the 204Pb tracer, data for the
fecal excretion of 206Pb tracer and endoge-
nous total Pb exhibited similar trends.
Because this reduction in fecal Pb excretion
with succimer treatment was small compared
to the increase in urinary excretion, the over-
all elimination of body Pb was still substan-
tially increased with succimer treatment.
Succimer decreased the retention of Pb
in the body. The effect of succimer to
decrease the net body retention of Pb is con-
sistent with its effect on increasing urinary
Pb excretion, relative to the vehicle group
(Figure 2). A reduction in body Pb retention
was evident with the recovery of both oral
206Pb and iv 204Pb tracers, again indicating
that succimer acts equally on Pb from past
chronic exposures and recent oral exposures
concurrent with treatment (Figure 3). This
outcome is consistent with several previous
rodent studies which showed that oral suc-
cimer decreased the whole-body retention
(10) and tissue accumulation (27) of Pb
derived from concurrent oral Pb exposures.
These data are in contrast with a previous
rodent study of several other chelating agents,
including BAL, citrate, and penicillamine,
which suggested that these agents may
increase the body absorption and retention of
Pb from exposures suffered concurrent with
treatment (11).
Although succimer signiﬁcantly decreased
the whole-body retention of Pb, the large
majority of the administered 204Pb and
absorbed oral 206Pb tracers were retained in
the body (> 77%; Figure 3), despite treatment
with succimer. This result is not due to the
incomplete collection of excreted Pb tracers
because most (e.g., > 80%) of the total 5-day
urinary and endogenous fecal excretion of
both tracers occurred over the ﬁrst 3 days of
treatment (daily endogenous fecal and urine
data not shown). This is surprising because
the majority of absorbed succimer remains in
the extracellular compartment (28,29) and
binds Pb with high afﬁnity (12). Nevertheless,
this outcome is supported by a previous study
in rodents, which suggested that succimer
treatment increased the enrichment of GI-
absorbed Pb into the skeleton while also caus-
ing increased urinary excretion of Pb (30).
Gastrointestinal absorption and excre-
tion of Pb in the absence of succimer ther-
apy. The relative absorption (~ 65%, fasting
conditions), and subsequent excretion
(3.9%) and retention (61%) of orally dosed
206Pb tracer in the vehicle group are in gen-
eral agreement with the ranges observed in
previous studies in monkeys (31,32).
Further, we observed that the excretion of
absorbed Pb via urinary and endogenous
fecal routes were comparable in magnitude.
These latter results are consistent with studies
in humans (33), monkeys (31), and rodents
(34–36), and collectively demonstrate that
endogenous fecal excretion is signiﬁcant as a
route of Pb elimination from the body.
Effects of succimer on BPb level. The sig-
nificant reductions in total BPb levels over
the first 8 days of succimer treatment are
consistent with the larger data set containing
these animals (n = 22–24/treatment) that
showed significant reductions in BPb level
over both the ﬁrst and second chelation regi-
mens (17). These data are also consistent
with studies in adult monkeys (37) and stud-
ies in children (1,25). Our observation that
total BPb levels in the vehicle group did not
measurably decline over the study period
may simply be attributed to the fact that oral
Pb exposure to these animals had ceased at
52 weeks of age, 12 weeks before the present
study. As such, the reduction in BPb level
with cessation of exposure had already
reached an asymptotic function of slow
decline when this study was conducted.
Clinical relevance. The succimer placebo-
controlled and double-stable Pb isotope tracer
design of the present study was ideally suited
to deﬁnitively address the effects of succimer
on the GI absorption and body retention of
Pb. The juvenile monkey model used here
closely approximates human metabolism for
both Pb (17,38) and succimer (12,39,40),
and thus is the most appropriate model avail-
able for studies on the effects of succimer on
the disposition of GI Pb in children. Adult
primates, including humans, are not well
suited for estimating GI Pb absorption in
juveniles because of the confounding effects
of age (32,41,42). Moreover, existing data
suggest that there may be species differences
(rodents vs. primates) in the pharmacokinet-
ics of succimer (12,39), suggesting that rodent
studies on some effects of succimer may not
directly extrapolate to humans. Finally, the
Pb exposure levels and succimer treatment
regimens are comparable to those experienced
by Pb-poisoned children, and the adminis-
tered oral 206Pb tracer dose is well within the
range of oral daily exposure suffered by Pb-
exposed children (~ 116 µg/day or 562
nmol/day) (43).
The ability of succimer to reduce GI Pb
absorption has important implications for the
clinical treatment of Pb-poisoned children.
Our results suggest that children who con-
tinue to be exposed to Pb during succimer
chelation are not likely to be at risk of
increased GI Pb uptake due to succimer
treatment. However, this does not reduce the
importance of primary prevention of Pb
exposures to children, nor does it support the
use of succimer as a prophylactic for Pb
exposure, because substantial amounts of Pb
from the GI tract were absorbed and retained
in the body despite the reductions in GI Pb
absorption caused by succimer. 
Although the animal model used in this
study is highly relevant to childhood Pb
intoxication, care should be taken in extrap-
olating the results from this study to chil-
dren because the experimental conditions
used here do not cover the broad range of
conditions that could be encountered clini-
cally. For instance, these animals received
optimal nutrition, a continuous steady expo-
sure to Pb early in life, a fasting period
before administration of the oral 206Pb tracer
and first succimer dose, and only a single
oral dose of Pb (tracer) immediately (within
15 min) before beginning succimer treat-
ment. It is likely that the nutritional and Pb
exposure history of these monkeys differed
from that experienced by children suffering
from elevated Pb exposure. Thus, although
the present study indicates that succimer does
not increase GI Pb absorption, we cannot
deﬁnitively conclude that succimer can safely
be given to children while they have ongoing
Pb exposures. Finally, the outcomes reported
here should not be extrapolated to succimer
treatment regimens in which succimer is
administered by a different route because
previous studies in rodents have shown that
parenteral administration of succimer
increased the GI absorption of Pb (10).
Summary
These results support the hypotheses that
oral succimer therapy reduces the absorption
of Pb from the GI tract and subsequently
reduces the body retention of Pb. These out-
comes have important clinical implications
for the out-patient treatment of Pb-poisoned
children with succimer because Pb exposure
may continue during treatment in some of
those children due to the scarcity of Pb-safe
housing and uncertainties in identifying and
remediating environmental Pb exposures.
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